Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
$0.06
+3.5%
$0.07
$0.05
$0.13
$9.43M1.396,110 shs1,220 shs
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
$0.43
+30.6%
$0.38
$0.25
$0.48
$36.86M1.08913,992 shs214,616 shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.50
+2.3%
$0.53
$0.39
$3.75
$35.06M-0.02414,723 shs355,832 shs
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$1.39
+2.2%
$1.67
$1.26
$16.94
$35.58M2.06118,846 shs76,512 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
+3.54%+5.93%-1.08%-5.02%-35.70%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
+0.95%+1.67%+15.76%+41.53%+21.19%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
+2.28%-0.08%-9.27%-1.77%-78.11%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
+2.21%+6.92%-8.55%-39.04%-52.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
$0.06
+3.5%
$0.07
$0.05
$0.13
$9.43M1.396,110 shs1,220 shs
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
$0.43
+30.6%
$0.38
$0.25
$0.48
$36.86M1.08913,992 shs214,616 shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.50
+2.3%
$0.53
$0.39
$3.75
$35.06M-0.02414,723 shs355,832 shs
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$1.39
+2.2%
$1.67
$1.26
$16.94
$35.58M2.06118,846 shs76,512 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
+3.54%+5.93%-1.08%-5.02%-35.70%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
+0.95%+1.67%+15.76%+41.53%+21.19%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
+2.28%-0.08%-9.27%-1.77%-78.11%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
+2.21%+6.92%-8.55%-39.04%-52.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
0.00
N/AN/AN/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
3.00
Buy$3.88809.62% Upside
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
3.00
Buy$7.331,369.61% Upside
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
3.00
Buy$8.50511.51% Upside

Current Analyst Ratings Breakdown

Latest BETRF, IGC, RANI, and SNTI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/8/2025
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$12.00
(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
N/AN/AN/AN/A($0.04) per shareN/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
$1.33M29.15N/AN/A$0.08 per share5.33
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$1.03M34.82N/AN/A$0.06 per share8.32
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
$2.56M14.20N/AN/A$5.31 per share0.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
-$2.55M-$0.01N/AN/AN/AN/A-609.07%9/23/2025 (Estimated)
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
-$13M-$0.07N/AN/AN/A-714.16%-122.44%-88.40%N/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$30.02M-$0.91N/AN/AN/AN/A-1,258.76%-97.97%11/13/2025 (Estimated)
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-$52.79M-$8.95N/AN/AN/AN/A-223.98%-76.02%11/13/2025 (Estimated)

Latest BETRF, IGC, RANI, and SNTI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.19-$0.18+$0.01-$0.18N/AN/A
8/7/2025Q2 2025
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
-$0.58-$0.56+$0.02-$0.56$1.30 million$0.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
N/AN/AN/AN/AN/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
N/AN/AN/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
N/AN/AN/AN/AN/A
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
N/A
0.04
0.04
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
0.02
1.15
0.98
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
2.75
0.54
0.54
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
N/A
3.26
3.26

Institutional Ownership

CompanyInstitutional Ownership
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
0.01%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
3.87%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
30.19%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
25.73%

Insider Ownership

CompanyInsider Ownership
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
34.77%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
23.66%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
45.08%
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
3.12%
CompanyEmployeesShares OutstandingFree FloatOptionable
BetterLife Pharma Inc. stock logo
BETRF
BetterLife Pharma
7151.84 million99.05 millionNot Optionable
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
6190.81 million54.60 millionN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
11071.87 million39.47 millionOptionable
Senti Biosciences, Inc. stock logo
SNTI
Senti Biosciences
426.16 million25.34 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BetterLife Pharma stock logo

BetterLife Pharma OTCMKTS:BETRF

$0.06 +0.00 (+3.54%)
As of 09/16/2025 03:18 PM Eastern

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

IGC Pharma stock logo

IGC Pharma NYSEMKT:IGC

$0.43 +0.10 (+30.63%)
Closing price 09/16/2025 03:58 PM Eastern
Extended Trading
$0.42 0.00 (-0.70%)
As of 09/16/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

Rani Therapeutics stock logo

Rani Therapeutics NASDAQ:RANI

$0.50 +0.01 (+2.28%)
Closing price 09/16/2025 04:00 PM Eastern
Extended Trading
$0.50 0.00 (-0.20%)
As of 09/16/2025 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Senti Biosciences stock logo

Senti Biosciences NASDAQ:SNTI

$1.39 +0.03 (+2.21%)
Closing price 09/16/2025 04:00 PM Eastern
Extended Trading
$1.38 0.00 (-0.36%)
As of 09/16/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.